15 patients responded to treatment with a rise in Hb concentration of more than 2 gm/dl. SC administration was found to be acceptable, convenient more effective in treating anemia in CAPD patients. It was also associated with an improved QoL and can very well be thought of as an optimal route of EPO administration in CAPD patients. Additionally, in the same dialysis unit, it was found that CAPD patients required a lower dose via the SC route than HD patients did via the IV route for maintaining target Hb levels. This evidence concerns the gene GSTM1 and anemia (phenotype).